Zacks: Brokerages Expect Madrigal Pharmaceuticals Inc (MDGL) Will Post Earnings of -$0.93 Per Share
Analysts expect Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) to report earnings per share (EPS) of ($0.93) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Madrigal Pharmaceuticals’ earnings. The lowest EPS estimate is ($1.04) and the highest is ($0.84). Madrigal Pharmaceuticals posted earnings of ($0.45) per share in the same quarter last year, which indicates a negative year over year growth rate of 106.7%. The firm is scheduled to announce its next quarterly earnings results on Tuesday, May 14th.
According to Zacks, analysts expect that Madrigal Pharmaceuticals will report full year earnings of ($3.99) per share for the current fiscal year, with EPS estimates ranging from ($4.44) to ($3.60). For the next year, analysts expect that the business will post earnings of ($4.97) per share, with EPS estimates ranging from ($5.40) to ($4.48). Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Madrigal Pharmaceuticals.
Madrigal Pharmaceuticals (NASDAQ:MDGL) last posted its quarterly earnings data on Wednesday, February 27th. The biopharmaceutical company reported ($0.75) EPS for the quarter, meeting analysts’ consensus estimates of ($0.75). During the same quarter last year, the business earned ($0.67) earnings per share.
NASDAQ MDGL traded down $1.75 during trading on Wednesday, reaching $103.81. The company’s stock had a trading volume of 62,866 shares, compared to its average volume of 240,553. The firm has a market cap of $1.63 billion, a PE ratio of -46.76 and a beta of 1.19. Madrigal Pharmaceuticals has a twelve month low of $91.56 and a twelve month high of $325.98.
Several large investors have recently modified their holdings of the company. Vanguard Group Inc boosted its holdings in Madrigal Pharmaceuticals by 52.7% during the third quarter. Vanguard Group Inc now owns 706,318 shares of the biopharmaceutical company’s stock worth $151,243,000 after buying an additional 243,664 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Madrigal Pharmaceuticals by 52.7% during the third quarter. Vanguard Group Inc. now owns 706,318 shares of the biopharmaceutical company’s stock worth $151,243,000 after buying an additional 243,664 shares in the last quarter. Point72 Asset Management L.P. purchased a new stake in Madrigal Pharmaceuticals during the third quarter worth about $20,300,000. BlackRock Inc. boosted its holdings in Madrigal Pharmaceuticals by 17.7% during the third quarter. BlackRock Inc. now owns 575,019 shares of the biopharmaceutical company’s stock worth $123,130,000 after buying an additional 86,520 shares in the last quarter. Finally, Frontier Capital Management Co. LLC purchased a new stake in Madrigal Pharmaceuticals during the fourth quarter worth about $9,454,000. 58.28% of the stock is currently owned by institutional investors and hedge funds.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.